Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia

Abstract
Machine learning can be used to define subtypes of psychiatric conditions based on shared clinical and biological foundations, presenting a crucial step toward establishing biologically based subtypes of mental disorders. With the goal of identifying subtypes of disease progression in schizophrenia, here we analyzed cross-sectional brain structural magnetic resonance imaging (MRI) data from 4,291 individuals with schizophrenia (1,709 females, age=32.5 years±11.9) and 7,078 healthy controls (3,461 females, age=33.0 years±12.7) pooled across 41 international cohorts from the ENIGMA Schizophrenia Working Group, non-ENIGMA cohorts and public datasets. Using a machine learning approach known as Subtype and Stage Inference (SuStaIn), we implemented a brain imaging-driven classification that identifies two distinct neurostructural subgroups by mapping the spatial and temporal trajectory of gray matter (GM) loss in schizophrenia. Subgroup 1 (n=2,622) was characterized by an early cortical-predominant loss (ECL) with enlarged striatum, whereas subgroup 2 (n=1,600) displayed an early subcortical-predominant loss (ESL) in the hippocampus, amygdala, thalamus, brain stem and striatum. These reconstructed trajectories suggest that the GM volume reduction originates in the Broca’s area/adjacent fronto-insular cortex for ECL and in the hippocampus/adjacent medial temporal structures for ESL. With longer disease duration, the ECL subtype exhibited a gradual worsening of negative symptoms and depression/anxiety, and less of a decline in positive symptoms. We confirmed the reproducibility of these imaging-based subtypes across various sample sites, independent of macroeconomic and ethnic factors that differed across these geographic locations, which include Europe, North America and East Asia. These findings underscore the presence of distinct pathobiological foundations underlying schizophrenia. This new imaging-based taxonomy holds the potential to identify a more homogeneous sub-population of individuals with shared neurobiological attributes, thereby suggesting the viability of redefining existing disorder constructs based on biological factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the grant from Science and Technology Innovation 2030-Brain Science and Brain-Inspired Intelligence Project (No. 2022ZD0212800). This work was supported by National Natural Science Foundation of China (No. 82202242, 82071997). This work was supported by the projects from China Postdoctoral Science Foundation (No. BX2021078, 2021M700852). This work was supported by the Shanghai Rising-Star Program (No. 21QA1408700) and the Shanghai Sailing Program (22YF1402800) from Shanghai Science and Technology Committee. This work was supported by National Key R&D Program of China (No. 2019YFA0709502), the grant from Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX01), ZJ Lab, and Shanghai Center for Brain Science and Brain-Inspired Technology, and the grant from the 111 Project (No. B18015).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was carried out under the approve from the Medical Research Ethics Committees of Fudan University (Number: FE222711).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Subject Area
- Addiction Medicine (408)
- Allergy and Immunology (720)
- Anesthesia (214)
- Cardiovascular Medicine (3042)
- Dermatology (258)
- Emergency Medicine (456)
- Epidemiology (12963)
- Forensic Medicine (12)
- Gastroenterology (848)
- Genetic and Genomic Medicine (4773)
- Geriatric Medicine (441)
- Health Economics (747)
- Health Informatics (3028)
- Health Policy (1096)
- Hematology (405)
- HIV/AIDS (952)
- Medical Education (450)
- Medical Ethics (119)
- Nephrology (490)
- Neurology (4545)
- Nursing (242)
- Nutrition (671)
- Oncology (2365)
- Ophthalmology (666)
- Orthopedics (264)
- Otolaryngology (332)
- Pain Medicine (296)
- Palliative Medicine (86)
- Pathology (512)
- Pediatrics (1232)
- Primary Care Research (515)
- Public and Global Health (7136)
- Radiology and Imaging (1587)
- Respiratory Medicine (940)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (505)
- Toxicology (63)
- Transplantation (218)
- Urology (187)